Table 3. Baseline characteristics of study population according to survival or not .
| Parameter | Alive N = 109 | Expired N = 31 | p value |
| Age (year) | 59.8 ± 12.1 | 65.4 ± 12.7 | 0.03 |
| Male gender (%) | 40 (37%) | 13 (42%) | 0.60 |
| Hypertension (%) | 55 (50%) | 23 (74%) | 0.02 |
| Diabetes mellitus (%) | 49 (45%) | 20 (65%) | 0.06 |
| Hyperlipidemia (%) | 42 (39%) | 11 (35%) | 0.79 |
| Smoker (%) | 16 (15%) | 8 (26%) | 0.15 |
| Duration of dialysis (yr) | 6.5 ± 3.4 | 7.5 ± 3.7 | 0.16 |
| Cilostazol treatment (%) | 10 (9%) | 10 (32%) | 0.001 |
| Albumin (g/dl) | 3.91 ± 0.32 | 3.75 ± 0.40 | 0.03 |
| Hemoglobin (g/dl) | 9.8 ± 1.2 | 9.9 ± 1.2 | 0.84 |
| Fasting glucose (mg/dl) | 141 ± 64 | 173 ± 85 | 0.03 |
| Total cholesterol (mg/dl) | 187 ± 39 | 186 ± 44 | 0.91 |
| LVEF | 0.62 ± 0.13 | 0.55 ± 0.15 | 0.04 |
| Ankle-brachial index | 0.94 ± 0.21 | 0.87 ± 0.26 | 0.11 |
| hsCRP (mg/dl) | 2.32 ± 1.95 | 2.42 ± 2.01 | 0.82 |
| Thrombospondin-1 (ug/ml) | 3.84 ± 2.16 | 5.66 ± 3.93 | < 0.001 |
hsCRP, high sensitivity C-reactive protein; LVEF, left ventricular ejection fraction.